Fig. 1.
Results of DiversiLab (bioMérieux, La Balme-les-Grottes, France) analysis. The horizontal similarity line showed the cut-off to separate different clones.
that bla OXA-72 was plasmid-located in all isolates. Plasmid analysis using the A. baumannii PCR-based replicon typing (AB-PBRT) scheme revealed that all French isolates possessed a plasmid of ca. 20 kb in size belonging to the GR12 family plasmid, as defined previously [4] , whereas the Colombian isolate was negative for this PCR. Shotgun DNA cloning was then performed to identify the genetic structure surrounding the bla OXA-72 gene. It revealed very similar structures to those identified on the GR12 plasmid-type and bla OXA-72 -positive plasmid pMMD identified in a clinical isolate of A. baumannii from Spain [5] . Altogether, these data indicated that these three plasmids, although originating from different strains, were likely the same.
Genotypic comparison was performed by DiversiLab following the manufacturer's instructions (bioMérieux, La Balme-les-Grottes, France). The clinical isolate of OXA-72-producing A. pittii 2688 from Colombia was used as a reference strain for comparison [3] . Genotyping analysis showed that the four isolates corresponded to three distinct clones (A-C) (Fig. 1) , with the Colombian isolate being distantly related to the French isolates. Two isolates, namely RA2 and RA3, were closely related. These two isolates have been recovered, respectively, in northern and southern suburb hospitals of Paris in 2011 and 2013. The remaining isolate recovered in another city in France was not related to the others.
This study constitutes the very first report of OXA-72-producing A. pittii in Europe following the initial identification of an OXA-72-producing A. pittii in Colombia. The fact that the same clone has been recovered in two different hospital settings 2 years apart likely indicated that this clone might be more widespread than expected. The difficulties in identifying A. pittii species might underestimate their clinical relevance, in accordance with a series of recent studies showing that non-baumannii Acinetobacter spp. were more clinically significant than expected. Competing interests: None declared. 
